Expert Video Report on Renal Cell Carcinoma

ASCO GU 2019

Speaker: Bradley McGregor

Reporting from ASCO GU, Bradley McGregor (Boston) comments on the results from main studies on Renal cell carcinoma that were presented during this meeting:

  • Abstract 544: Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma; Toni K. Choueiri
  • Abstract 543: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma: phase III KEYNOTE-426 study; Thomas Powles
  • Abstract 547: Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab or sunitinib in patients with advanced renal cell carcinoma; Nizar M. Tannir
  • Abstract 546: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma: Results from KEYNOTE-427 cohort B; David F. McDermott
  • Abstract 548: Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation; Rana R. McKay